Real-world prevalence of autoimmune disease (AD) among patients receiving immune checkpoint inhibitors (ICI) in ASCO CancerLinQ’s Discovery® Database
Although patients with AD are routinely excluded from ICI clinical trials, evidence suggests they may be receiving ICI therapy once approved. This study sought to understand the prevalence of AD among all patients receiving ICIs in real world clinical care, as well as in advanced non-small cell lung cancer (aNSCLC) alone, and to describe the characteristics of ICI patients with and without evidence of AD. This analysis of real-world data finds that a large proportion of pts receiving ICI may have pre-existing AD. Further examination is warranted to examine how AD status may impact outcomes.